No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo

• https://bit.ly/3D3tO6b

Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80

• Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in…

Avoid IFX drug holidays! In this study 400+ pts Dvlpmt of ADAs associated w/ ▶️RA vs. SPA OR 2.1 ▶️Smoking OR 1.8 ▶️Drug holidays > 11 weeks OR 4.1 ▶️High DA OR 1.5 while ◀️Concomitant IS drug OR 0.4 ◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh

Upadacitinib 56-wk efficacy/safety (mod to severe PsA) 🔹Comparable or ⬆️efficacy vs adalimumab 🔹Efficacy maintained, and 15mg vs 30mg doses similar at 56wks 🔹No new safety findings @ 56wks 🔹🚫inc risk VTE, MACE, cancer vs ada https://t.co/NlKvBrwDxB #ACR21 Abst#1345 @RheumNow

• Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic A…

#ACR21 @RheumNow Abst#0364 by Wetterslev et al. sought to identify axSpA characteristics of patients tapered off TNFI and showed clinical and radiographic improvement. 🔽52% were tapered off ⭐️The highest predictor of success is a low physician global VAS score

Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX: 💠IFX-naive: improved disease activity 💠IFX-switched: maintained stable disease 💠No new safety concerns https://t.co/VGBicnq15w #ACR21 Abst#0817 @RheumNow

• Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis …

A study at #ACR21 by Charite-University Medicine Berlin researchers suggests taking tumor necrosis factor inhibitor (TNFi) #biologics earlier in the course of disease could slow down spinal progression in #AxialSpondyloarthritis patients. https://t.co/lDkaMkOcez

Abst1344 #ACR21 @RheumNow observational study of pts w/PsA treated w/b&tsDMARD:pts who achieve MDA (22.8% of pts at 6 mo) more likely to maintain the initiated bDMARD or tsDMARD Rx & less likely to switch from the initiated bDMARD/tsDMARD https://t.co/egFDHV3eQs